The content on this site is intended for healthcare professionals only
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths.
Now, researchers have shown that men experience more harm than good from routine PSA screening, according to research presented by Professor Mathieu Boniol, at the 2013 European Cancer Congress (ECC 2013).
Read more on ecancerNews
Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing
Powering equity in cancer care through digital health
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Psychological issues in familial cancer
Best practice in HRRm testing in patients with metastatic prostate cancer
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Nigeria solidarity support fund and the annual youth engagement campaign on HPV
Social determinants of health in primary care
